WallStreetZenWallStreetZen

NASDAQ: AMED
Amedisys Inc Stock Forecast, Predictions & Price Target

Analyst price target for AMED

Based on 2 analysts offering 12 month price targets for Amedisys Inc.
Min Forecast
$100.00+3.34%
Avg Forecast
$100.50+3.85%
Max Forecast
$101.00+4.37%

Should I buy or sell AMED stock?

Based on 2 analysts offering ratings for Amedisys Inc.
Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 50%
Hold
1 analysts 50%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their AMED stock forecasts and price targets.

AMED stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-04-25
lockedlocked$00.00+00.00%2024-03-25

1 of 1

Forecast return on equity

Is AMED forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
17.53%

Forecast return on assets

Is AMED forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

AMED revenue forecast

What is AMED's revenue in the next 3 years based on estimates from 7 analysts?
Avg 1 year Forecast
$2.3B+3.41%
Avg 2 year Forecast
$2.5B+9.27%
Avg 3 year Forecast
$2.6B+16.66%
AMED's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

AMED revenue growth forecast

How is AMED forecast to perform vs Medical Care Facilities companies and vs the US market?
Company
4.68%
Industry
5.18%
Market
9.3%
AMED's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
AMED's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

AMED vs Medical Care Facility Stocks

TickerPricePrice TargetUp/downsideConsensus
AMED$96.77$100.50+3.85%Buy
SGRY$25.19$43.00+70.70%Strong Buy
AGL$5.99$8.20+36.89%Hold
PACS$27.66$31.00+12.08%Strong Buy
LFST$5.81$9.33+60.64%Strong Buy

Amedisys Stock Forecast FAQ

Is Amedisys Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: AMED) stock is to Buy AMED stock.

Out of 2 analysts, 0 (0%) are recommending AMED as a Strong Buy, 1 (50%) are recommending AMED as a Buy, 1 (50%) are recommending AMED as a Hold, 0 (0%) are recommending AMED as a Sell, and 0 (0%) are recommending AMED as a Strong Sell.

If you're new to stock investing, here's how to buy Amedisys stock.

What is AMED's revenue growth forecast for 2024-2026?

(NASDAQ: AMED) Amedisys's forecast annual revenue growth rate of 4.68% is not forecast to beat the US Medical Care Facilities industry's average forecast revenue growth rate of 5.18%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.3%.

Amedisys's revenue in 2024 is $2,251,407,000.On average, 7 Wall Street analysts forecast AMED's revenue for 2024 to be $76,080,531,716, with the lowest AMED revenue forecast at $75,418,236,732, and the highest AMED revenue forecast at $77,147,693,230. On average, 5 Wall Street analysts forecast AMED's revenue for 2025 to be $80,390,089,226, with the lowest AMED revenue forecast at $78,143,488,441, and the highest AMED revenue forecast at $83,362,704,908.

In 2026, AMED is forecast to generate $85,825,822,694 in revenue, with the lowest revenue forecast at $85,825,822,694 and the highest revenue forecast at $85,825,822,694.

What is AMED's forecast return on assets (ROA) for 2024-2026?

(NASDAQ: AMED) forecast ROA is N/A, which is lower than the forecast US Medical Care Facilities industry average of N/A.

What is AMED's Price Target?

According to 2 Wall Street analysts that have issued a 1 year AMED price target, the average AMED price target is $100.50, with the highest AMED stock price forecast at $101.00 and the lowest AMED stock price forecast at $100.00.

On average, Wall Street analysts predict that Amedisys's share price could reach $100.50 by Apr 25, 2025. The average Amedisys stock price prediction forecasts a potential upside of 3.85% from the current AMED share price of $96.77.

What is AMED's forecast return on equity (ROE) for 2024-2026?

(NASDAQ: AMED) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.